semaglutide 7.2 mg clinical trial Once-weekly 7·2 in adults with obesity (STEP UP): a randomised, controlled, phase 3b Impact of patient characteristics on

More GLP-1 was needed to have the same biological effect, meaning they were resistant to GLP-1." Mouse Studies Confirm GLP-1 Resistance The findings were so unexpected that the researchers spent several years testing whether the result was real

Weight stigma and bias: standards of care in overweight and obesity-2025

The quantities of weight loss achievable with semaglutide GLP-1 are comparable to what individuals may achieve through more expensive surgical interventions, which are also associated with unwanted risks, side effects, and considerable downtime

[11] Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine. Accessed: Nov

For patients who have not achieved their desired results with earlier GLP-1 medications, or who are seeking the most potent medically available option, Zepbound may represent a powerful new path forward

Commercial plans offer the best chance, while Medicare remains limited for obesity-only use today and Medicaid depends on the state